Functionalisation of extracellular vesicles with cyclic-RGDyC potentially for glioblastoma targeted intracellular drug delivery
Source abstract
Abstract
With the intrinsic ability to cross the blood-brain barrier, small extracellular vesicles (sEVs) hold promise as endogenous brain-targeted drug delivery nano-platforms for glioblastoma (GBM) treatment. To increase GBM targetability, this study aimed to functionalise sEVs with cyclic arginine-glycine-aspartic acid-tyrosine-cysteine (cRGDyC), a ligand for integrin (αvβ3) that is overexpressed in GBM cells. Firstly, the intrinsic cellular uptake of sEVs derived from GBM U87 and pancreatic cancer MIA PaCa-2 cells was investigated on the donor cells. To obtain functionalised sEVs (cRGDyC-sEVs), DSPE-mPEG2000-maleimide was incubated with the selected (U87) sEVs, and cRGDyC was subsequently conjugated to the maleimide groups via a thiol-maleimide coupling reaction. The GBM cell targetability and intracellular trafficking of cRGDyC-sEVs were evaluated on U87 cells by fluorescence and confocal microscopy, using unmodified sEVs as a reference. The cytotoxicity of doxorubicin-loaded vesicles (Dox@sEVs, Dox@cRGDyC-sEVs) was compared with a standard liposome formulation (Dox@Liposomes) and free Dox. Both U87 and MIA PaCa-2 cell-derived sEVs displayed tropism with the former being >4.9-fold more efficient to be internalised into U87. Therefore, the U87-derived sEVs were chosen for GBM-targeting. Approximately 4000 DSPE-mPEG2000-maleimide were inserted onto each sEV with cRGDyC conjugated to the maleimide group. The cell targetability of cRGDyC-sEVs to U87 cells improved 2.4-fold than natural sEVs. Despite their proneness to be colocalised with endosomes/lysosomes, both Dox@sEVs and Dox@cRGDyC-sEVs showed superior cytotoxicity to U87 GBM cells compared to Dox@Liposomes, particularly Dox@cRGDyC-sEVs. Overall, U87-derived sEVs were successufully conjugated with cRGDyC via a PEG linker, and cRGDyC-sEVs were demonstrated to be a potnetial integrin-targeting drug delivery vehicle for GBM treatment. Graphic abstract.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Extracellular vesicles in disease · MicroRNA in disease regulation · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (59)
Show source-provided references
1. Potential of long non-coding RNAs as a therapeutic target and molecular markers in glioblastoma pathogenesis10.1016/j.heliyon.2021.e06502 ↗
2. Cholesterol-rich nanoemulsion (LDE) as a novel drug delivery system to diagnose, delineate, and treat human glioblastoma10.1016/j.msec.2021.111984 ↗
3. A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy10.1016/j.omto.2022.02.012 ↗
4. Exosomes and biomimetic nanovesicles-mediated anti-glioblastoma therapy: a head-to-head comparison10.1016/j.jconrel.2021.07.004 ↗
5. Cancer therapy based on extracellular vesicles as drug delivery vehicles10.1016/j.jconrel.2020.08.018 ↗
6. Emerging prospects of extracellular vesicles for brain disease theranostics10.1016/j.jconrel.2021.12.024 ↗
7. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines10.1080/20013078.2018.1535750 ↗
8. Separation, characterization, and standardization of extracellular vesicles for drug delivery applications10.1016/j.addr.2021.04.027 ↗
9. Recent advancement and technical challenges in developing small extracellular vesicles for cancer drug delivery10.1007/s11095-021-02988-z ↗
10. Extracellular vesicles as a drug delivery system: a systematic review of preclinical studies10.1016/j.addr.2021.05.011 ↗
11. Biodistribution of extracellular vesicles following administration into animals: a systematic review10.1002/jev2.12085 ↗
12. Cellular internalization of exosomes occurs through phagocytosis10.1111/j.1600-0854.2010.01041.x ↗
13. pH-responsive hyaluronate-anchored extracellular vesicles to promote tumor-targeted drug delivery10.1016/j.carbpol.2018.08.141 ↗
14. Hyaluronan decoration of milk exosomes directs tumor-specific delivery of doxorubicin10.1016/j.carres.2020.108032 ↗
15. Engineering approaches for effective therapeutic applications based on extracellular vesicles10.1016/j.jconrel.2020.11.062 ↗
16. Engineering hybrid exosomes by membrane fusion with liposomes10.1038/srep21933 ↗
17. Improved cardiac-specific delivery of RAGE siRNA within small extracellular vesicles engineered to express intense cardiac targeting peptide attenuates myocarditis10.1016/j.omtn.2021.04.018 ↗
18. Approaches to surface engineering of extracellular vesicles10.1016/j.addr.2021.03.020 ↗
19. Stabilization of exosome-targeting peptides via engineered Glycosylation*10.1074/jbc.M114.621383 ↗
20. Advances in extracellular vesicle functionalization strategies for tissue regeneration
21. Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance10.1016/j.biomaterials.2019.119475 ↗
22. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time10.1016/j.jconrel.2016.01.009 ↗
23. Vitamin A-coupled stem cell-derived extracellular vesicles regulate the fibrotic cascade by targeting activated hepatic stellate cells in vivo10.1016/j.jconrel.2021.06.031 ↗
24. Combined integrin α(v)β(3) and lactoferrin receptor targeted docetaxel liposomes enhance the brain targeting effect and anti-glioma effect10.1186/s12951-021-01180-0 ↗
25. Tumor acidic microenvironment-induced drug release of RGD peptide nanoparticles for cellular uptake and cancer therapy10.1016/j.colsurfb.2021.111673 ↗
26. Cyclic-RGDyC functionalized liposomes for dual-targeting of tumor vasculature and cancer cells in glioblastoma: an in vitro boron neutron capture therapy study10.18632/oncotarget.16625 ↗
27. The role of glutathione conjugation on the transcellular transport process of PEGylated liposomes across the blood brain barrier10.1016/j.ijpharm.2022.122152 ↗
28. Increased exosome production from tumour cell cultures using the integra CELLine culture system10.1016/j.jim.2008.03.001 ↗
29. Protein corona components of polyethylene glycol-conjugated organosilica nanoparticles modulates macrophage uptake10.1016/j.colsurfb.2020.111527 ↗
30. Macrophage-derived extracellular vesicles as drug delivery Systems for Triple Negative Breast Cancer (TNBC) therapy10.1007/s11481-019-09884-9 ↗
31. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy10.1016/j.biomaterials.2021.120784 ↗
32. Exosomes: biogenesis, biologic function and clinical potential10.1186/s13578-019-0282-2 ↗
33. Dual pH-sensitive liposomes with low pH-triggered sheddable PEG for enhanced tumor-targeted drug delivery10.2217/nnm-2018-0510 ↗
34. Extracellular vesicle heterogeneity: subpopulations, isolation techniques, and diverse functions in cancer progression10.3389/fimmu.2018.00738 ↗
35. A simple approach to re-engineering small extracellular vesicles to circumvent endosome entrapment10.1016/j.ijpharm.2022.122153 ↗
36. Cancer cell-type tropism is one of crucial determinants for the efficient systemic delivery of cancer cell-derived exosomes to tumor tissues10.1016/j.ejpb.2019.10.005 ↗
37. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming10.1038/85438 ↗
38. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity10.1023/A:1014434732752 ↗
39. PEG-lipid post insertion into drug delivery liposomes quantified at the single liposome level10.1002/admi.201801807 ↗
40. Trojan horse treatment based on PEG-coated extracellular vesicles to deliver doxorubicin to melanoma in vitro and in vivo10.1080/15384047.2021.2003656 ↗
41. PEG-benzaldehyde-hydrazone-lipid based PEG-sheddable pH-sensitive liposomes: abilities for endosomal escape and long circulation10.1007/s11095-018-2429-y ↗
42. Adsorption of cationic peptides to solid surfaces of glass and plastic10.1371/journal.pone.0122419 ↗
43. Synthesis of a bi-functional dendrimer-based nanovehicle co-modified with RGDyC and TAT peptides for neovascular targeting and penetration10.1016/j.ijpharm.2016.01.068 ↗
44. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region10.1016/j.jconrel.2015.10.039 ↗
45. Development of long-circulating pH-sensitive liposomes to circumvent gemcitabine resistance in pancreatic cancer cells10.1007/s11095-016-1902-8 ↗
46. Integrins in cancer: biological implications and therapeutic opportunities10.1038/nrc2748 ↗
47. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond10.1016/S0142-9612(03)00343-0 ↗
48. Real time imaging of single extracellular vesicle pH regulation in a microfluidic cross-flow filtration platform10.1038/s42003-021-02965-7 ↗
49. Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells10.1007/s11095-014-1353-z ↗
50. Exosome-mimetic nanoplatforms for targeted cancer drug delivery10.1186/s12951-019-0517-8 ↗
51. Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery10.1016/j.actbio.2019.05.054 ↗
52. A nanodrug consisting of doxorubicin and exosome derived from mesenchymal stem cells for osteosarcoma treatment in vitro10.2147/IJN.S218988 ↗
53. Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects10.2147/IJN.S125573 ↗
54. Doxorubicin conjugated functionalizable carbon dots for nucleus targeted delivery and enhanced therapeutic efficacy10.1039/C6NR00247A ↗
55. Quantitative characterization of extracellular vesicle uptake and content delivery within mammalian cells10.1038/s41467-021-22126-y ↗
56. Multifunctional targeted liposomal drug delivery for efficient glioblastoma treatment10.18632/oncotarget.17976 ↗
57. pH-temperature dual-sensitive nucleolipid-containing stealth liposomes anchored with PEGylated AuNPs for triggering delivery of doxorubicin10.1016/j.ijpharm.2022.121691 ↗
58. Anti-tumor effect of liposomes containing extracted murrayafoline a against liver cancer cells in 2D and 3D cultured models10.1515/chem-2022-0122 ↗
59. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles10.1038/ncomms2282 ↗